Lilly goes back to Nimbus for an oral obesity drug in $55M deal
Lilly goes back to Nimbus for an oral obesity drug in $55M deal
Body unavailable. Use the original source.
Lilly goes back to Nimbus for an oral obesity drug in $55M deal
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.